Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
18 February 2025
At the extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39426005 (the "Company"), held on 21 January 2025, it was resolved to change the nominal value of the shares of the Company from DKK 0.001 to DKK 1 by way of a reverse share split at a ratio of 1,000:1 to the effect that 1,000 shares of a nominal value of DKK 0.001 each are consolidated into one (1) share of a nominal value of DKK 1.
On 21 January 2025, the Company issued a redemption notice to all shareholders, initiating a four-week redemption period which expires on 19 February 2025 at 11:59:59 PM CET. Shareholdings below 1,000 shares (of nominally DKK 0.001 each) and excess shares (i.e. any remaining shares of nominally DKK 0.001 that cannot be consolidated into a whole number of shares or a nominal value of DKK 1 each) (both referred to as "Excess Shares") (after the four-week redemption period) will be redeemed in cash by the Company in accordance with the time schedule set out below. The redemption will be completed at a price of DKK 0.0023 per share with a nominal value of DKK 0.001 in accordance with the redemption notice.
Payment for any redemption of Excess Shares is expected to take place on 26 February 2025 and will be subject to withholding tax on dividends in accordance with applicable rules. Any redemption amount payable to each shareholder holding Excess Shares (redemption price multiplied by its number of Excess Shares) which have more than two decimals will be rounded to two decimals to facilitate payment. Any costs related to the redemption process with VP Securities A/S will be covered by the Company.
After the completion of the share consolidation, all shareholders will receive an updated statement from VP Securities A/S (Euronext Securities), reflecting the new number of shares in their share deposit account each with a nominal value of DKK 1.
As set out in the redemption notice, holders of Excess Shares who disagree with the redemption price may, no later than three months after the date of the share redemption, i.e. no later than on 26 May 2025, request that the redemption price be determined by an appraiser (in Danish: skønsmand) appointed by the court at the Company's registered office (in Danish: hjemsted), cf. Section 70(2) of the Danish Companies Act. The appraiser must determine the redemption price in accordance with Section 67(3) of the Danish Companies Act. After this three-month period expires on 26 May 2025, such shareholders can no longer request an appraisal of the redemption price.
The change of the nominal share value will take effect on 25 February 2025. The new ISIN for the new shares (of nominally DKK 1) is DK0063631999.
As a result of the reverse share split, the share capital of the Company is divided as follows: (i) 3,991,101 shares of nominally DKK 1 and (ii) 234 shares of nominally DKK 0.001 (held by the Company).
The remaining time schedule for the reverse share split is as follows:
| Last day of trading of the existing shares (nom. value per share: DKK 0.001) (ISIN DK0061410487) | 21 February 2025 |
| First day of trading of the new shares (nom. value per share: DKK 1) (ISIN DK0063631999) | 24 February 2025 |
| Holding of shares of nom. DKK 0,001 exchanged to new shares of nom. DKK 1 through VP Securities A/S (Euronext Securities) | 25 February 2025 |
| Payment of redeemed Excess Shares | 26 February 2025 |
| Deadline for holders of Excess Shares to contest the redemption price | 26 May 2025 |
Best regards,
DanCann Pharma A/S